Loading patent…
OwnerAriel B. Abramov, George A. Gaitanaris +8inventors
InventorsAriel B. Abramov, George A. Gaitanaris, Marc A. Gavin, Heidi LeBlanc, Zachary Matthew James, Jason O'Neill, Peter K. Nollert von Specht, Mohammed Oukka, Munehisa Yabuki, Ami Yamamoto
Estimating the term…
Provided herein are compositions comprising a toxin-derived domain, a translocation domain derived from diphtheria toxin domain B (DTB), and one or more targeting moieties that bind a cancer-related surface antigen or receptor. The toxin domain has DNase activity and is linked to the translocation domain by a protease-cleavable linker. Also provided are methods of using the compositions for the treatment of cancer.
A molecule comprising a toxin domain, a translocation domain, and one or more targeting moieties that bind an antigen or receptor present on the surface of a cancer cell;
2-3. (canceled)
7-12. (canceled)
(canceled)
(canceled)
19-20. (canceled)
(canceled)
(canceled)
30-31. (canceled)
34-35. (canceled)
38-39. (canceled)
42-44. (canceled)
(canceled)
48-52. (canceled)
The molecule of claim 44, wherein at least one targeting moiety is derived from an anti-B-cell maturation antigen (BCMA) antibody.
55-58. (canceled)
The molecule of claim 44, wherein at least one targeting moiety is derived from an anti-CD19 antibody.
61-64. (canceled)
The molecule of claim 44, wherein at least one targeting moiety is derived from an anti-claudin18.2 (CLDN18.2) antibody.
66-67. (canceled)
69-73. (canceled)
The molecule of claim 44, wherein at least one targeting moiety is derived from an anti-human epidermal growth factor receptor 2 (HER2) antibody.
(canceled)
77-81. (canceled)
The molecule of claim 44, wherein at least one targeting moiety is derived from an anti-mesothelin (MSLN) antibody.
(canceled)
85-89. (canceled)
The molecule of claim 44, wherein at least one targeting moiety is derived from an anti-glypican-3 (GPC3) antibody.
(canceled)
93-97. (canceled)
The molecule of claim 44, wherein at least one targeting moiety is derived from an anti-epidermal growth factor receptor (EGFR) antibody.
(canceled)
101-105. (canceled)
The molecule of claim 44, wherein at least one targeting moiety is derived from an anti-trophoblast cell surface antigen 2 (TROP2) antibody.
(canceled)
109-113. (canceled)
116-117. (canceled)
123-124. (canceled)
126-127. (canceled)
166-167. (canceled)
171-174. (canceled)
Dependencies are inferred from the claim text.